Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001140361-23-053352
Filing Date
2023-11-15
Accepted
2023-11-15 08:49:28
Documents
1

Document Format Files

Seq Description Document Type Size
1 DEFA14A ny20014758x1_defa14a.htm DEFA14A 17445
  Complete submission text file 0001140361-23-053352.txt   18383
Mailing Address 3545 CRAY COURT SAN DIEGO CA 92121
Business Address 3545 CRAY COURT SAN DIEGO CA 92121 858-332-3410
Mirati Therapeutics, Inc. (Filer) CIK: 0001576263 (see all company filings)

EIN.: 462693615 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-35921 | Film No.: 231409164
SIC: 2834 Pharmaceutical Preparations